# CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

> **NCT02839954** · PHASE1,PHASE2 · UNKNOWN · sponsor: **PersonGen BioTherapeutics (Suzhou) Co., Ltd.** · enrollment: 10 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Non-small Cell Lung Cancer
- Pancreatic Carcinoma
- Triple-Negative Invasive Breast Carcinoma
- Malignant Glioma of Brain
- Colorectal Carcinoma
- Gastric Carcinoma

## Interventions

- **BIOLOGICAL:** anti-MUC1 CAR-pNK cells

## Key facts

- **NCT ID:** NCT02839954
- **Lead sponsor:** PersonGen BioTherapeutics (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2017-07
- **Final completion:** 2018-07
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2016-12-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02839954

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02839954, "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT02839954. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*